Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.

ABSTRACT:

Background

An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice.

Methods

We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016. These patients had been admini

SUBMITTER: Nakamura Y 

PROVIDER: S-EPMC5363594 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature